In general, and after reviewing various evidence that showed a contrast in the use of EZH2 inhibitors in cancers, especially mesothelioma, it seems that testing the response to EZH2 should be carefully evaluated before using these molecules as therapy (64). The gene discussed is EZH2; the disease is cancer.